Source:http://linkedlifedata.com/resource/pubmed/id/17416472
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2007-4-30
|
| pubmed:abstractText |
Molecular modification with polyethylene glycol (PEGylation) is an effective approach to improve protein biostability and decrease protein immunogenic activity. To create a PEGylated recombinant human acid fibroblast growth factor (rhaFGF) and improve its bio-stability, we have produced a rhaFGF mutant (rhaFGF(ser98,132)) by replacing the 98th and the 132nd cysteine residues with serine residues. The rhaFGF(ser98,132) that retains the bioactivity of rhaFGF was then site-specifically conjugated with PEG-maleimide at the 31st cysteine residue. PEGylated rhaFGF(ser98,132) has less effect than the native rhaFGF(ser98,132) on stimulating 3T3 cell proliferation in vitro; however, its biostability at a prolonged incubation under various temperatures and resistance to trypsinization were significantly enhanced, and half-life time in vivo was elongated while its immunogenicity was significantly decreased. The physiological function of PEGylated rhaFGF(ser98,132) was evaluated in a rat model of retinal ischemia/reperfusion injury, showing that in vivo supplementation of PEGylated rhaFGF(ser98,132) provided a significantly better protection than the native rhaFGF(ser98,132) against ischemia/reperfusion-induced retinal morphological changes and lipid peroxidation. The protection is probably mediated by antioxidant protective mechanisms.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0378-4274
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
25
|
| pubmed:volume |
170
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
146-56
|
| pubmed:meshHeading |
pubmed-meshheading:17416472-Animals,
pubmed-meshheading:17416472-BALB 3T3 Cells,
pubmed-meshheading:17416472-Cell Proliferation,
pubmed-meshheading:17416472-Cell Survival,
pubmed-meshheading:17416472-Disease Models, Animal,
pubmed-meshheading:17416472-Drug Stability,
pubmed-meshheading:17416472-Female,
pubmed-meshheading:17416472-Fibroblast Growth Factors,
pubmed-meshheading:17416472-Humans,
pubmed-meshheading:17416472-Intraocular Pressure,
pubmed-meshheading:17416472-Lipid Peroxidation,
pubmed-meshheading:17416472-Mice,
pubmed-meshheading:17416472-Mice, Inbred BALB C,
pubmed-meshheading:17416472-Mutagenesis, Site-Directed,
pubmed-meshheading:17416472-Polyethylene Glycols,
pubmed-meshheading:17416472-Rats,
pubmed-meshheading:17416472-Rats, Sprague-Dawley,
pubmed-meshheading:17416472-Recombinant Proteins,
pubmed-meshheading:17416472-Reperfusion Injury,
pubmed-meshheading:17416472-Retina,
pubmed-meshheading:17416472-Retinal Degeneration
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Enhanced protection of modified human acidic fibroblast growth factor with polyethylene glycol against ischemia/reperfusion-induced retinal damage in rats.
|
| pubmed:affiliation |
Chinese-American Research Institute for Diabetic Complications, School of Pharmaceutical Science, Wenzhou Medical College, China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|